Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Standardized Insect Venom Allergenic Extract [EPC]
Myosotis Arvensis is a botanical active ingredient primarily classified as a non-standardized plant allergenic extract. It is utilized in diagnostic testing and certain immunotherapeutic formulations to manage environmental sensitivities.
Name
Myosotis Arvensis
Raw Name
MYOSOTIS ARVENSIS
Category
Standardized Insect Venom Allergenic Extract [EPC]
Drug Count
8
Variant Count
8
Last Verified
February 17, 2026
About Myosotis Arvensis
Myosotis Arvensis is a botanical active ingredient primarily classified as a non-standardized plant allergenic extract. It is utilized in diagnostic testing and certain immunotherapeutic formulations to manage environmental sensitivities.
Detailed information about Myosotis Arvensis
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Myosotis Arvensis.
Myosotis Arvensis, commonly known as the Field Forget-me-not, is a flowering plant belonging to the Boraginaceae family. In a clinical and pharmacological context, Myosotis Arvensis is primarily utilized as a Non-Standardized Plant Allergenic Extract [EPC]. While the regulatory classification may sometimes associate it with broader categories such as Standardized Insect Venom Allergenic Extract [EPC] or even l-Thyroxine [EPC] in specific multi-constituent database mappings, its primary medical utility remains rooted in the field of allergology and integrative medicine. As an allergenic extract, it is derived from the raw botanical material and processed into a solution intended for either diagnostic skin testing or for use in allergen immunotherapy (desensitization).
According to the FDA-approved labeling for allergenic extracts, these substances are intended for the diagnosis and treatment of patients who exhibit specific IgE-mediated hypersensitivity. Myosotis Arvensis belongs to a class of drugs called Allergenic Extracts, which work by modulating the patient's immune response to environmental triggers. The FDA has historically overseen these extracts under the Biologics Control Act, ensuring that the manufacturing processes maintain a level of consistency, even when 'standardized' units (such as BAU or AU) are not applicable to the specific extract.
The mechanism of action for Myosotis Arvensis depends heavily on its clinical application. In diagnostic settings, such as percutaneous (scratch) or intradermal skin testing, the extract is introduced to the mast cells within the skin's dermal layer. If the patient has pre-existing IgE antibodies specific to Myosotis Arvensis proteins, these antibodies will cross-link upon exposure, triggering mast cell degranulation. This release of histamine and other inflammatory mediators results in a 'wheal and flare' reaction, which healthcare providers use to confirm sensitization.
In a therapeutic context, such as subcutaneous immunotherapy (SCIT), the mechanism is far more complex and involves a fundamental shift in the immune system's profile. Regular, escalating doses of the Myosotis Arvensis extract are administered to induce 'immunological tolerance.' At the molecular level, this involves:
Traditional pharmacokinetic parameters (Absorption, Distribution, Metabolism, and Elimination) are not typically characterized for allergenic extracts like Myosotis Arvensis in the same way they are for small-molecule synthetic drugs. This is because the 'active' components are a complex mixture of proteins and glycoproteins.
Myosotis Arvensis is indicated for several specific clinical scenarios, primarily within the realm of allergy and immunology:
Myosotis Arvensis is available in several specialized forms, depending on the therapeutic intent:
> Important: Only your healthcare provider can determine if Myosotis Arvensis is right for your specific condition. The use of allergenic extracts must be supervised by a physician trained in the management of anaphylaxis.
Dosage for Myosotis Arvensis is highly individualized and must be determined through a process of clinical titration. There is no 'standard' dose that applies to all patients.
Immunotherapy follows a two-phase schedule:
Myosotis Arvensis extracts may be used in children, but the dosage must be approached with extreme caution. Pediatric dosing is generally based on the same titration principles as adult dosing, rather than weight-based calculations. However, children under the age of 5 may be at a higher risk for systemic reactions and may have difficulty communicating early symptoms of anaphylaxis. Healthcare providers typically evaluate the risk-benefit ratio carefully for young pediatric patients.
No specific dosage adjustments are provided for patients with renal impairment, as the systemic load of the protein extract is minimal. However, patients with severe renal disease may have a reduced capacity to handle systemic allergic reactions.
Hepatic impairment does not typically require a dose adjustment for Myosotis Arvensis extracts, as the liver is not the primary site of clearance for these biological proteins.
Elderly patients (over 65) should be screened for underlying cardiovascular disease before starting Myosotis Arvensis immunotherapy. If an elderly patient is taking beta-blockers, the dose may need to be withheld or adjusted due to the risk of refractory anaphylaxis.
Myosotis Arvensis extracts are almost exclusively administered by a healthcare professional in a clinical setting.
If a dose in the build-up phase is missed, the next dose may need to be reduced to ensure safety.
An overdose of Myosotis Arvensis (administering a concentration higher than the patient's current tolerance level) can lead to severe systemic reactions or anaphylaxis.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer these extracts without medical guidance.
Most patients receiving Myosotis Arvensis extracts will experience some form of local reaction. These are generally considered expected and manageable.
> Warning: Stop taking Myosotis Arvensis and call your doctor immediately if you experience any of these.
When used correctly for immunotherapy, Myosotis Arvensis is generally not associated with long-term organ toxicity. However, prolonged use of any allergenic extract requires ongoing monitoring of the patient's immune status. There is a theoretical risk of developing new sensitivities to other components within the extract, though this is clinically rare. In homeopathic concentrations, long-term side effects are virtually non-existent due to the extreme dilution of the active material.
While Myosotis Arvensis itself may not have an individual 'Black Box' label, the entire class of Allergenic Extracts carries a general warning regarding the risk of severe non-fatal and fatal systemic reactions.
Summary of Warning Content:
Report any unusual symptoms to your healthcare provider. Even a 'small' systemic symptom like itchy palms or a scratchy throat should be reported immediately.
Myosotis Arvensis is a potent biological substance. It is not a standard medication that can be used without strict specialist oversight. The most critical safety factor is the prevention and management of IgE-mediated systemic reactions. Patients must be in a stable state of health before receiving an injection; for example, if a patient is currently experiencing an acute asthma flare or a fever, the injection should be postponed.
No specific FDA black box warning exists solely for the 'Myosotis Arvensis' plant species; however, it falls under the mandatory class labeling for Allergenic Extracts. This labeling states that these products can cause severe life-threatening systemic reactions, including anaphylaxis. It mandates that these products should not be administered to patients with severe, unstable, or steroid-dependent asthma, as these individuals are at the highest risk for a fatal outcome if a reaction occurs.
Patients undergoing Myosotis Arvensis immunotherapy do not typically require routine blood counts or liver function tests. Instead, monitoring focuses on:
Myosotis Arvensis does not have a direct sedative effect. However, if a patient experiences a systemic reaction or receives epinephrine to treat a reaction, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.
Alcohol consumption should be avoided for several hours before and after an injection. Alcohol causes vasodilation (widening of blood vessels), which can potentially increase the rate of allergen absorption and exacerbate the severity of an allergic reaction.
Unlike many medications, Myosotis Arvensis immunotherapy does not require a 'taper' to avoid withdrawal. However, stopping immunotherapy prematurely will result in the loss of the accumulated immunological tolerance, and allergic symptoms will likely return upon environmental exposure.
> Important: Discuss all your medical conditions with your healthcare provider before starting Myosotis Arvensis.
For each major interaction, the mechanism is usually related to the body's ability to either mount or suppress an inflammatory response, or the body's ability to respond to emergency rescue medications.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
There are several conditions where Myosotis Arvensis must NEVER be used:
These conditions require a careful risk-benefit analysis by an allergist:
Patients who are allergic to other members of the Boraginaceae family (such as Borage, Comfrey, or Lungwort) may exhibit cross-reactivity with Myosotis Arvensis. This means they may have a positive skin test or a reaction to the extract even if they have never been directly exposed to the Field Forget-me-not before.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Myosotis Arvensis.
Myosotis Arvensis extracts are categorized as Pregnancy Category C (under the older FDA system). This means that animal reproduction studies have not been conducted, and it is not known if the extract can cause fetal harm.
It is not known whether Myosotis Arvensis proteins are excreted in human milk. However, because these are large proteins that are likely broken down in the mother's digestive system if ingested, or processed by the immune system if injected, the risk to a nursing infant is considered very low. Breastfeeding is generally not a contraindication for receiving allergenic extracts.
Immunotherapy with Myosotis Arvensis is generally not recommended for children under the age of 5. This is primarily because young children may not be able to describe the early, subtle symptoms of a systemic reaction (such as an itchy throat or a 'funny taste' in the mouth), which could delay the administration of life-saving epinephrine. For older children, the treatment is effective and follows adult dosing principles.
In patients over 65, the decision to use Myosotis Arvensis must involve a thorough cardiovascular screening. The elderly are more likely to have underlying coronary artery disease or hypertension, which increases the risk of complications if anaphylaxis occurs. Furthermore, the elderly are more likely to be on multiple medications (polypharmacy) that could interact with allergy treatments.
Patients with end-stage renal disease (ESRD) or those on dialysis may have altered immune function. While the extract does not require renal-based dosing, these patients should be monitored closely for any unusual immune responses.
There are no specific guidelines for Myosotis Arvensis in hepatic impairment. Because the extract is a biological protein processed by the immune system rather than a drug metabolized by the cytochrome P450 system in the liver, standard dosing is typically used.
> Important: Special populations require individualized medical assessment.
Myosotis Arvensis acts as an immunomodulator. When administered in small, increasing doses, it interacts with the Dendritic Cells (DCs) of the immune system. These cells process the plant proteins and present them to T-lymphocytes. In an allergic individual, this presentation usually results in a Th2 response. Immunotherapy forces the immune system to switch to a 'tolerant' state by inducing the production of Regulatory T-cells (Tregs). These Tregs secrete IL-10, which suppresses IgE production by B-cells and instead promotes the production of IgG4. This IgG4 serves as a 'decoy,' binding to the Myosotis Arvensis allergens before they can reach the IgE on the surface of mast cells, thereby preventing the allergic cascade.
The pharmacodynamic effect of Myosotis Arvensis is not immediate. While a skin test shows a reaction within 20 minutes, the therapeutic effect (reduction in allergy symptoms) usually takes 3 to 6 months to begin and 12 to 18 months to reach peak efficacy. The duration of the effect can last for several years even after the treatment is discontinued, a phenomenon known as 'disease modification.'
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Local) |
| Protein Binding | Primarily to IgE and IgG4 antibodies |
| Half-life | Variable (Proteins degraded within hours to days) |
| Tmax | 15–30 minutes for local skin reaction |
| Metabolism | Proteolysis by immune cells |
| Excretion | Minimal renal excretion of peptide fragments |
Myosotis Arvensis extracts contain a complex mixture of:
Myosotis Arvensis is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic category of Allergen Immunotherapy Agents. It is distinct from 'standardized' extracts (like Grass or Dust Mite) because there is no federally mandated potency test for this specific plant species.
Common questions about Myosotis Arvensis
Myosotis Arvensis is primarily used as an allergenic extract for the diagnosis and treatment of specific allergies. In a clinical setting, an allergist may use a liquid form of this plant to perform skin tests to see if a patient is allergic to its pollen or proteins. If a significant allergy is found, the extract can be used in 'allergy shots' (immunotherapy) to help desensitize the patient's immune system over time. Additionally, it is used in certain homeopathic preparations for lymphatic support, though these uses are based on different traditional principles. Always consult an allergist to determine if this extract is appropriate for your symptoms.
The most common side effects are local reactions at the site where the extract was injected or applied. This typically includes redness, itching, and a small raised bump or swelling similar to a mosquito bite. These reactions usually appear within minutes and disappear within a few hours. Some patients may also experience mild fatigue or a slight increase in their typical allergy symptoms, like sneezing or a runny nose, shortly after treatment. While these are common, any reaction that grows larger than a few centimeters should be reported to your doctor.
It is generally advised to avoid alcohol on the days you receive a Myosotis Arvensis injection. Alcohol can cause your blood vessels to dilate, which might increase the speed at which the allergen is absorbed into your bloodstream, potentially raising the risk of a systemic allergic reaction. Furthermore, alcohol can mask the early symptoms of anaphylaxis, such as dizziness or flushing, making it harder for you or your doctor to recognize an emergency. To ensure maximum safety, wait at least several hours after your appointment before consuming alcohol. Always follow the specific lifestyle restrictions provided by your allergy clinic.
Myosotis Arvensis is generally not started as a new treatment during pregnancy because of the risk of a systemic reaction. If a pregnant woman were to have a severe allergic reaction to the shot, the resulting drop in her blood pressure could reduce the oxygen supply to the baby. However, if a woman is already on a stable 'maintenance' dose and has shown they can tolerate it well, many doctors will choose to continue the treatment. The decision is always based on a careful balance of the mother's allergy severity versus the potential risks. You must inform your allergist immediately if you become pregnant while receiving these injections.
Myosotis Arvensis immunotherapy is a long-term commitment and does not provide instant relief like an antihistamine pill. Most patients begin to notice a decrease in their allergy symptoms after 3 to 6 months of consistent injections during the 'build-up' phase. However, the full benefits of the treatment are usually not realized until the patient has been on a maintenance dose for 12 to 18 months. A typical course of treatment lasts between 3 and 5 years to ensure that the immune system remains 'trained' even after the shots are stopped. Your doctor will monitor your progress to decide when it is safe to discontinue the therapy.
Yes, you can stop taking Myosotis Arvensis injections suddenly without experiencing physical withdrawal symptoms, as it is not an addictive substance. However, stopping the treatment before the recommended 3-to-5-year mark usually means that your allergy symptoms will eventually return. The 'tolerance' that your immune system built up will gradually fade without the regular 'reminders' provided by the injections. If you need to stop treatment due to side effects or life changes, discuss it with your allergist first. They can help you understand how stopping will affect your long-term allergy management.
If you miss a dose of Myosotis Arvensis, you should contact your allergy clinic as soon as possible to reschedule. You should not simply wait until your next scheduled appointment, as the timing of these injections is very important for safety. If you have missed more than one or two weeks, your doctor may need to reduce the dose of your next injection to prevent a reaction. Missing too many doses may require you to go back to an earlier, lower concentration and start the build-up process again. Consistency is the key to both the safety and the effectiveness of allergen immunotherapy.
There is no clinical evidence to suggest that Myosotis Arvensis allergenic extracts cause weight gain. The extract consists of proteins and glycoproteins administered in very small amounts, which do not affect the body's metabolism or appetite centers. If you experience weight gain while undergoing immunotherapy, it is likely due to other factors, such as lifestyle changes or other medications you may be taking, like oral steroids for asthma. If you have concerns about weight changes, it is best to discuss them with your primary care physician to identify the underlying cause. Myosotis Arvensis is considered weight-neutral.
Myosotis Arvensis can be taken with most medications, but there are some very important exceptions. You must tell your doctor if you are taking beta-blockers (often used for blood pressure or heart issues), as these can make an allergic reaction much harder to treat. You should also mention if you are taking MAO inhibitors or certain antidepressants. While you can continue taking your regular allergy medications like Claritin or Flonase, you should usually avoid taking antihistamines on the day of a diagnostic skin test, as they can hide the results. Always provide your allergist with a complete list of your current medications.
The concept of 'generic' vs. 'brand name' works differently for allergenic extracts like Myosotis Arvensis than it does for regular pills. These extracts are biological products, and different manufacturers may produce their own versions of Myosotis Arvensis extract. While they are not usually called 'generics,' various laboratories produce extracts that are considered clinically equivalent. However, doctors generally prefer not to switch between different manufacturers' extracts once a patient has started treatment, as there can be slight variations in potency. Your clinic will typically stick with the same supplier throughout your entire course of immunotherapy.